A Randomized, Single-Blind, Placebo-Controlled, Single-Ascending Dose Crossover Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Orally Administered ARRY-300 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2012
At a glance
- Drugs ARRY 300 (Primary)
- Indications Cancer; Inflammation
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Array BioPharma
- 25 Apr 2009 Actual initiation date (Jan 2009) added as reported by ClinicalTrials.gov.
- 25 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 25 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.